Oncology Meeting Innovations
Translating Innovation Into Patient Care

Upcoming Calendar

Global Summit on Genitourinary Malignancies
Nov
1
to Nov 3

Global Summit on Genitourinary Malignancies

Oncology Meeting Innovations’ (OMI’s) Global Summit on Genitourinary Malignancies fosters discussion and debate on the evolution of treatment and features a focused approach towards individual patient populations through case-based discussions. New agents are changing the landscape and treatment paradigms so staying updated on new approaches is important for treatment for renal cell carcinoma, prostate cancer, and bladder cancer. Compelling data on the effects of novel strategies, such as chimeric antigen receptor T-cell therapy, checkpoint inhibition, and next-generation antibody therapy, have led to an explosion of new information and agents in development for patients with genitourinary malignancies. In response to these changes, the Summit assembles translational researchers, clinical researchers, and key community oncologists to address the challenges of this rapidly evolving area of oncology.

View Event →
Annual Expert Forum on Thoracic Malignancies
Nov
16
to Nov 17

Annual Expert Forum on Thoracic Malignancies

Key Objectives

  • Discuss the latest data on molecular segmentation of thoracic malignancies and how they might impact treatment decisions
  • Review the data on currently available agents and new targets in clinical trials
  • Gain understanding of the integration of novel therapies with standards of care
  • Discuss the rationale behind novel therapeutics and their potential efficacy and safety, both as single agents and in combination with other therapies
  • Review and discuss the expanding role of immunotherapy in the treatment of lung cancer
  • Discuss the role of the tumor microenvironment and the extent to which it can be manipulated to achieve better efficacy and less toxicity
View Event →
Expert Forum on Breast Cancer
Dec
14
to Dec 15

Expert Forum on Breast Cancer

KEY OBJECTIVES  

  • Assess genomic tools that support breast cancer treatment options
  • Deliberate treatment strategies for Triple Negative breast cancer and metastatic breast cancer
  • Describe the optimal management ER+ and HER2+ breast cancers and debate optimal endocrine therapy and management of side effects
  • Explore the current use of immunotherapy including immune checkpoint inhibitors, monoclonal antibodies, and cancer vaccines and its rationale for combinations with other therapeutic types including radiation therapy and chemotherapy
  • Examine current CDK4/6 and PARP inhibitors and the rationales for combining these inhibitors with other therapies
  • Debate adjuvant and neoadjuvant strategies for optimal treatment
View Event →

Expert Forum on T-Cell Engagers in Immuno-Oncology
Sep
28
to Sep 29

Expert Forum on T-Cell Engagers in Immuno-Oncology

OMI's Expert Forum on Cellular Therapies is a one-and-a-half day think-tank fostering debate and discussion aroudn t-cell engagers in immuno-oncology. This program will cover recent data, emerging agents and the changing landscape in CAR-T therapy, vaccine therapies and other cellular therapies outside of checkpoint inhibitors

View Event →
Expert Forum on Gastrointestinal Malignancies
Sep
7
to Sep 8

Expert Forum on Gastrointestinal Malignancies

  • Dallas Renaissance Hotel Addison (map)
  • Google Calendar ICS
  • Discuss the evolving role of anti-angiogenesis inhibition in CRC
  • Examine new anti-angiogenesis targets in CRC, HCC, and gastric cancer
  • Understand the patient selection for EGFR inhibition in GI malignancies
  •  Discuss the evolving role of second line therapy for gastric and pancreatic cancer
  • Review the role of innovative cytotoxic treatment in GI malignancies
  • Explore new targets for GI malignancies
View Event →
Multiple Myeloma Expert Forum
Aug
24
to Aug 25

Multiple Myeloma Expert Forum

Oncology Meeting Innovations’ (OMI’s) Expert Forum on Multiple Myeloma fosters debates on the rapidly expanding information on molecular diagnostics, genomic analysis, new molecular targets, and the evolution of care over the next 5 years of multiple myeloma.  There will be a focus on current research in the genomics and new molecular targets in myeloma including SLAMF7, CD38, HDAC, KSP, NEP, BCMA, checkpoint inhibitors, and others.  The meeting will also explore the role of next-generation IMiDs, proteasome inhibitors, and the impact of the microenvironment on myeloma resistance and survival.  The Expert Forum assembles a distinguished group of preclinical and translational experts for an open discussion on new data that will influence our knowledge of myeloma over the coming years.

View Event →
Regional Summit on Genitourinary Malignancies - Pasadena
Jul
28
8:00 AM08:00

Regional Summit on Genitourinary Malignancies - Pasadena

  • Discuss the treatment landscape for genitourinary malignancies
  • Examine the evolving role of genomics in the treatment of renal cell carcinoma, bladder cancer, and prostate cancer
  • Analyze therapies in late-stage development and how they will be utilized as treatment options
  • Engage with leading experts to deliberate newest practices and novel therapies
View Event →
Chronic Lymphocytic Leukemia Expert Forum
Jul
27
to Jul 28

Chronic Lymphocytic Leukemia Expert Forum

Oncology Meeting Innovations’ (OMI’s) Expert Forum on Chronic Lymphocytic Leukemia fosters debates on the rapidly expanding information on molecular diagnostics, genomic analysis, new molecular targets, and the evolution of care over the next five years of chronic lymphocytic leukemia treatment. There will be a focus on the current treatment of chronic lymphocytic leukemia and the integration of novel B-cell signaling inhibitors and other emerging therapeutic targets into the treatment paradigm. The meeting will also explore the frontline landscape, management of toxicities, assessment of response and progression, minimal residual disease, and other practical issues. The Expert Forum assembles a distinguished group of preclinical and translational experts for an open discussion on new data that will influence our knowledge of chronic lymphocytic leukemia over the coming years

View Event →
Regional Summit on Genitourinary Malignancies - NYC
Jul
21
8:00 AM08:00

Regional Summit on Genitourinary Malignancies - NYC

  • Discuss the treatment landscape for genitourinary malignancies
  • Examine the evolving role of genomics in the treatment of renal cell carcinoma, bladder cancer, and prostate cancer
  • Analyze therapies in late-stage development and how they will be utilized as treatment options
  • Engage with leading experts to deliberate newest practices and novel therapies
View Event →
Regional Summit on B-Cell and Plasma Cell Malignancies - Minneapolis
Jun
30
8:00 AM08:00

Regional Summit on B-Cell and Plasma Cell Malignancies - Minneapolis

  • Discuss how to assess risk in CLL
  • Review recent advances and new data for treating CLL, lymphoma, and multiple myeloma
  • Evaluate immunotherapy in B-cell malignancies
  • Examine advances in targeting BTK, PI3K, and BCL-2 inhibition
  • Discuss how to diagnose and treat Richter’s Transformation
  • Discuss how to treat indolent lymphoma after chemotherapy
View Event →
Non-Hodgkin & Hodgkin Lymphoma Expert Forum
Jun
22
to Jun 23

Non-Hodgkin & Hodgkin Lymphoma Expert Forum

  • 2201 North Stemmons Freeway Dallas, TX, 75207 United States (map)
  • Google Calendar ICS

Oncology Meeting Innovations’ (OMI’s) Expert Forum on Non-Hodgkin and Hodgkin Lymphoma fosters debates on the rapidly expanding information on molecular diagnostics, genomic analysis, new molecular targets, and the evolution of care over the next five years of non-Hodgkin and Hodgkin lymphoma.  There will be a focus on the integration of novel therapies, such as checkpoint inhibitors, CAR-T therapy, and ADCs, into the current treatment paradigm.  The meeting will also explore the management of toxicities, assessment of response and progression, and the influence of microenvironment on resistance and survival.  The Expert Forum assembles a distinguished group of preclinical and translational experts for an open discussion on new data that will influence our knowledge of lymphoma over the coming years.

View Event →
Expert Forum on Genitourinary Malignancies
May
4
to May 5

Expert Forum on Genitourinary Malignancies

KEY TOPICS

  • Review advances in genomics, including liquid biopsy technology, for prostate cancer, RCC, and bladder cancer
  • Discuss the evolving role of chemotherapy • Compare current and next-generation ADT in CRPC
  • Evaluate advantages and disadvantages of treating beyond progression in prostate cancer • Explore new immune approaches (e.g. checkpoint inhibitors and vaccines) to prostate cancer, RCC, and bladder cancer
  • Discuss optimal use of TKIs as single agents and combination strategies with immunotherapy in RCC • Assess combinations of chemotherapy and immunotherapy in bladder cancer
  • Discuss novel biomarker-guided treatment for RCC and bladder cancer
  • Review recent data on novel target inhibitors in prostate cancer, RCC, and bladder cancer
View Event →
5th Annual Summit on Hematologic Malignancies
Mar
14
to Mar 18

5th Annual Summit on Hematologic Malignancies

Our 5th Hematologic Malignancies meeting will be held on March 14th - 17th, 2018 in Whistler, BC, Canada. Indications covered at our Whistler meeting include Chronic Lymphocytic Leukemia, Multiple Myeloma, aggressive and indolent Lymphomas and Acute Leukemias. Steven Coutre, MD, Sundar Jagannath, MBBS, Michael Keating, MD, Alexander Perl, MD and Andrew Zelenetz, MD, PhD are chairing the summit. To register click here

View Event →
Acute Leukemias and Myeloproliferative Neoplasms
Jan
26
to Jan 27

Acute Leukemias and Myeloproliferative Neoplasms

  • Evolving biology of de novo AML and MDS-transformed AML
  • Molecular segmentation of AML, including FLT-3, and novel therapeutic targets
  • Current understanding of a genetic/epigenetic basis of classic MPNs  
  • The role of JAK inhibition and the development of new targets in MPN
  • The genomic landscape of ALL and novel targets for ALL, including T-cell engagers
View Event →
Expert Forum on Breast Cancer 2017
Dec
15
to Dec 16

Expert Forum on Breast Cancer 2017

Oncology Meeting Innovations’ (OMI’s) Expert Forum on Breast Cancer gathers key opinion leaders to discuss and debate the latest data and information in the field of breast cancer research. This forum will include topics related to triple-negative, inflammatory, and metastatic breast cancer, and aims to foster debate on the expanding information on pathogenesis, prevention, screening, diagnosis, and treatments. Discussions will focus on the preclinical, clinical, and translational research on the biology of tumors and their microenvironment, standards of care, current and recently approved approaches to therapy in immunotherapy, radiation therapy, and chemotherapy, and promising therapeutics in development. Current controversies and emerging issues in the field will be deliberated, along with the application of recent research findings and the optimization of individualized breast cancer therapy. This interactive forum will provide participants with opportunities to share their thoughts and opinions about the current breast cancer landscape and how to drive treatment strategies forward.

More Info

View Event →
3rd Annual Expert Forum on Thoracic Malignancies and Head and Neck Cancer
Nov
3
to Nov 4

3rd Annual Expert Forum on Thoracic Malignancies and Head and Neck Cancer

Oncology Meeting Innovations’ (OMI’s) 4th Annual Expert Forum on Thoracic Malignancies is a discussion-based meeting designed to engage top thought leaders in the important advances that will shape the landscape of NSCLC therapeutics over the next five years. The meeting will take a deep look at the latest data on novel strategies in development for patients with lung cancer and mesothelioma, gathering world experts in lung cancer to discuss and debate new targets, preclinical and clinical agents, the tumor immune microenvironment, and immune models. The meeting will feature 30 to 35 ten-minute lectures followed by group discussions, with the goal of presenting a robust, forward-looking assessment of current and upcoming therapies to advance treatment of NSCLC patients.

More Info

View Event →
Regional Summit on Acute Leukemias - West
Oct
21
8:00 AM08:00

Regional Summit on Acute Leukemias - West

Oncology Meetings Innovations invites you to participate in our 2017 Regional Summit on Acute Myeloid and Acute Lymphoblastic Leukemia. In this summit, we will discuss the current treatment landscape for acute leukemia and how the latest approved therapies can be incorporated into clinical practice. Along with newly approved compounds, topics will also include compounds in late-stage development with emerging data for targeted maintenance therapies.

The meetings will consist of informative 15-minute presentations followed by group discussions of the current practice in AML and ALL. This Regional Summit assembles a distinguished group of key opinion leaders to present the leading strategies for employing the latest advances in treatment and emerging data on FLT-3, CD33 antibody drug conjugates, next-generation hypomethylating agents. Additionally, the audience will have the opportunity to engage the leading experts in discussion on their various topics and contribute to case-studies based on these new therapies. We look forward to welcoming you to our Regional Summits.

More Info

View Event →
Regional Summit On Acute Leukemias - East
Oct
14
8:00 AM08:00

Regional Summit On Acute Leukemias - East

Oncology Meetings Innovations invites you to participate in our 2017 Regional Summit on Acute Myeloid and Acute Lymphoblastic Leukemia. In this summit, we will discuss the current treatment landscape for acute leukemia and how the latest approved therapies can be incorporated into clinical practice. Along with newly approved compounds, topics will also include compounds in late-stage development with emerging data for targeted maintenance therapies.

The meetings will consist of informative 15-minute presentations followed by group discussions of the current practice in AML and ALL. This Regional Summit assembles a distinguished group of key opinion leaders to present the leading strategies for employing the latest advances in treatment and emerging data on FLT-3, CD33 antibody drug conjugates, next-generation hypomethylating agents. Additionally, the audience will have the opportunity to engage the leading experts in discussion on their various topics and contribute to case-studies based on these new therapies. We look forward to welcoming you to our Regional Summits.

More Info

View Event →
Annual Multiple Myeloma Expert Forum
Aug
11
to Aug 12

Annual Multiple Myeloma Expert Forum

Oncology Meeting Innovations’ (OMI’s) Expert Forum on Multiple Myeloma fosters debates on the rapidly expanding information on molecular diagnostics, genomic analysis, new molecular targets, and the evolution of care over the next 5 years of multiple myeloma.  There will be a focus on current research in the genomics and new molecular targets in myeloma including SLAMF7, CD38, HDAC, KSP, NEP, BCMA, checkpoint inhibitors, and others.  The meeting will also explore the role of next-generation IMiDs, proteasome inhibitors, and the impact of the microenvironment on myeloma resistance and survival.  The Expert Forum assembles a distinguished group of preclinical and translational experts for an open discussion on new data that will influence our knowledge of myeloma over the coming years.

More Info

View Event →
Annual Chronic Lymphocytic Leukemia Expert Forum
Aug
4
to Aug 5

Annual Chronic Lymphocytic Leukemia Expert Forum

Oncology Meeting Innovations’ (OMI’s) Expert Forum on Chronic Lymphocytic Leukemia fosters debates on the rapidly expanding information on molecular diagnostics, genomic analysis, new molecular targets, and the evolution of care over the next five years of chronic lymphocytic leukemia treatment. There will be a focus on the current treatment of chronic lymphocytic leukemia and the integration of novel B-cell signaling inhibitors and other emerging therapeutic targets into the treatment paradigm. The meeting will also explore the frontline landscape, management of toxicities, assessment of response and progression, minimal residual disease, and other practical issues. The Expert Forum assembles a distinguished group of preclinical and translational experts for an open discussion on new data that will influence our knowledge of chronic lymphocytic leukemia over the coming years.
 

More Info

View Event →
Annual Lymphoma Non-Hodgkin and Hodgkin Expert Forum
Jul
14
to Jul 15

Annual Lymphoma Non-Hodgkin and Hodgkin Expert Forum

Oncology Meeting Innovations’ (OMI’s) Expert Forum on Non-Hodgkin and Hodgkin Lymphoma fosters debates on the rapidly expanding information on molecular diagnostics, genomic analysis, new molecular targets, and the evolution of care over the next five years of non-Hodgkin and Hodgkin lymphoma. There will be a focus on the integration of novel therapies, such as checkpoint inhibitors, CAR-T therapy, and ADCs, into the current treatment paradigm. The meeting will also explore the management of toxicities, assessment of response and progression, and the influence of microenvironment on resistance and survival. The Expert Forum assembles a distinguished group of preclinical and translational experts for an open discussion on new data that will influence our knowledge of lymphoma over the coming years.

More Info

View Event →